Tylenol Use Linked to Development of Lymphoma

According to a new study, individuals who take Tylenol regularly may be at a higher risk for cancer. The research, conducted by scientists at the University of Washington, suggests that people who are heavily reliant on acetaminophen are more likely to develop a variety of cancers, including lymphoma.

"We found that high use of acetaminophen, one of the most frequently used medications worldwide, was associated with an almost twofold increased risk of incident hematologic malignancies," said lead researcher Dr. Roland Walter, an assistant professor of medicine in the division of hematology.

In order to attain their findings, the researchers on hand collected information on 64,839 men and women between the ages of 50 and 76. Among them, researchers noted 577 cases of blood cancers.

As per an investigation, it was found that those who used acetaminophen for a minimum of four days a week over the course of four years were at a higher risk of developing cancers including, but not limited to: myeloid neoplasms, non-Hodgkin lymphomas and plasma cell disorders.

"Acetaminophen use on the majority of the days over many years appears to be associated with this new adverse effect," Walter said. "However, the study does not allow one to conclude a causal relationship," he added.

Bonnie Jacobs, a spokeswoman for McNeil Consumer Healthcare, a division of McNeil-PPC, Inc., the maker of Tylenol, was quick to reply. She noted that "Tylenol has over 50 years of clinical history to support its safety and efficacy” and "We appreciate the assessment of the authors that further studies would be needed before it is possible to draw any conclusions about the use of acetaminophen, and we welcome additional research in this area."

The results from this report originally appeared in the May 9 online edition of Journal of Clinical Oncology.

photo by Ragesoss

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap